CagriSema vs Retatrutide
Two investigational obesity molecules at different stages: a Phase 3 amylin plus GLP-1 combination, and a Phase 2 triple agonist holding the larger number.
CagriSema
~20% in REDEFINE 1; amylin plus GLP-1 in one shot — promising, not yet approved.
Full CagriSema evidence reviewRetatrutide
~24% in its Phase 2 trial — the largest figure reported for any incretin, but still investigational.
Full Retatrutide evidence reviewSide by side
| CagriSema | Retatrutide | |
|---|---|---|
| Marketed for | Weight loss | Weight loss |
| Evidence grade | Clinical data | Clinical data |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | Investigational |
| How it's obtained | Research-only | Research-only |
| Key human source | REDEFINE 1, NEJM 2025 | Phase 2, NEJM 2023 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Neither is approved and neither can be prescribed; both remain research-stage. Retatrutide posted the bigger figure, about 24.2% at 12 mg in a 48-week Phase 2 trial of 338 adults, with a weight curve that had not clearly plateaued when the study closed. CagriSema's roughly 20% in REDEFINE 1 is a smaller number resting on more mature Phase 3 evidence, including a read-out in people who also have type 2 diabetes. They have not been compared directly, and neither has long-term outcomes data.
CagriSema fits if
You weigh trial stage above headline magnitude and want the combination that has already produced Phase 3 results in people with and without diabetes.
Retatrutide fits if
You are tracking the largest weight-loss signal reported for any incretin and accept that it is still mid-stage evidence.